SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS

The disclosure relates to substituted heteroarylpiperidine derivative (I) as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry these compounds of formula (I) are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC- 4R). The...

Full description

Saved in:
Bibliographic Details
Main Authors TERINEK, MIROSLAV, DEPPE, HOLGER, HERZNER, HOLGER, RUMMEY, CHRISTIAN, FEURER, ACHIM, SIENDT, HERVE, HENNEBOHLE, MARCO, WEYERMANN, PHILIPP, SOEBERDT, MICHAEL, NORDHOFF, SONJA
Format Patent
LanguageEnglish
Published 30.09.2011
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The disclosure relates to substituted heteroarylpiperidine derivative (I) as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry these compounds of formula (I) are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC- 4R). These agonists can be used for the treatment of diseases and disorders where the regulation of the MC- 4R is involved, particularly disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety and depression.
Bibliography:Application Number: NZ20080582153